7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Sio Gene Therapies, Inc
(NASDAQ:SIOX) 

SIOX stock logo

Sio Gene Therapies, Inc., a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the trea...

Founded: 2014
Full Time Employees: 38
CEO: Pavan Cheruvu  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
Sio Gene Therapies Op Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -0.82-0.71-0.59-0.47-0.35-0.24-0.120
Sio Gene Therapies Free Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -0.84-0.72-0.6-0.48-0.36-0.24-0.120
Sio Gene Therapies Cash Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.110.210.320.420.530.640.74
Sio Gene Therapies (GAAP) P/E ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -5.49-4.71-3.92-3.14-2.35-1.57-0.780
Sio Gene Therapies P/B ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.110.220.340.450.560.670.78
No extra charts and metrics for this ticker.